| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2016 | 151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs | Liao B.-C.; Bai Y.-Y.; Lin C.-C.; Lin S.-Y.; Lee Y.-F.; CHAO-CHI HO; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Yang J. | Journal of Thoracic Oncology | 1 | 1 | |
| 2016 | 205P: Visualizing ZO-1-mediated coupled migration between cancer and stromal cells in lung cancer metastasis via a 5-dimensional cell imaging system | Lu H.-H.; Chen B.-C.; Chen H.-W.; CHAO-CHI HO; Yu C.-J. | Journal of Thoracic Oncology | 0 | 0 | |
| 2002 | 8 Role of immunohistochemical expression of caveolin-1 in lung carcinoma | CHAO-CHI HO; Huang P.-H.; Yang P.-C.; Hsu S.-M. | Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas | 0 | 0 | |
| 2002 | 8 Role of immunohistochemical expression of caveolin-1 in lung carcinoma | CHAO-CHI HO; PEI-HSIN HUANG | Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas | 0 | 0 | |
| 2017 | Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib | CHAO-CHI HO; Liao W.-Y.; Lin C.-A.; Shih J.-Y.; Yu C.-J.; Chih-Hsin Yang J. | Journal of Thoracic Oncology | 88 | 93 | |
| 2011 | Admissions to intensive care unit of HIV-infected patients in the era of highly active antiretroviral therapy: Etiology and prognostic factors | Chiang H.-H.; Hung C.-C.; Lee C.-M.; Chen H.-Y.; Chen M.-Y.; Sheng W.-H.; Hsieh S.-M.; Sun H.-Y.; CHAO-CHI HO; Yu C.-J. | Critical Care | 45 | 48 | |
| 2011 | Admissions to intensive care unit of HIV-infected patients in the era of highly active antiretroviral therapy: Etiology and prognostic factors | Chong-Jen Yu; SZU-MIN HSIEH; WANG-HUEI SHENG; CHAO-CHI HO; HSIN-YUN SUN; CHIEN-CHING HUNG | Critical Care | 41 | 48 | |
| 2008 | Adrenal insufficiency in prolonged critical illness | Wu J.-Y.; Hsu S.-C.; Ku S.-C.; CHAO-CHI HO; Yu C.-J.; Yang P.-C. | Critical Care | 18 | 14 | |
| 2012 | Advanced non-small cell lung cancer in patients aged 45 years or younger: Outcomes and prognostic factors | Hsu C.-L.; Chen K.-Y.; Shih J.-Y.; CHAO-CHI HO; Yang C.-H.; Yu C.-J.; Yang P.-C. | BMC Cancer | 61 | 55 | |
| 2012 | Advanced non-small cell lung cancer in patients aged 45 years or younger: Outcomes and prognostic factors | Chong-Jen Yu; Hsu, Chia-Lin; Chen, Kuan-Yu; CHIA-LIN HSU; CHAO-CHI HO; Shih, Jin-Yuan; JIN-YUAN SHIH; Ho, Chao-Chi; Yang, Chih-Hsin; Yu, Chong-Jen; Yang, Pan-Chyr | BMC Cancer | 54 | 55 |  |
| 2014 | Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis | CHAO-CHI HO | Lung Cancer | 20 | 20 | |
| 2014 | Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis | Lin C.-H.; Lin M.-T.; Kuo Y.-W.; CHAO-CHI HO | Lung Cancer | 20 | 20 | |
| 2021 | Afatinib exerts immunomodulatory effects by targeting the pyrimidine biosynthesis enzyme CAD | Tu, Hsin Fang; Ko, Chun Jung; Lee, Ching Tai; Lee, Cheng Fan; Lan, Shao Wei; Lin, Hsin Hsien; Lin, Hsin Ying; CHIA-CHI KU; Lee, Der Yen; Chen, I. Chun; YA-HUI CHUANG; Caño-Ochoa, Francisco Del; Ramon-Maiques, Santiago; CHAO-CHI HO; MING-SHYUE LEE; GEEN-DONG CHANG | Cancer Research | | 0 | |
| 2020 | Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors | Yang C.-Y.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. | European Journal of Cancer | 18 | 19 | |
| 2020 | Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors | Ching-Yao Yang; Wei-Yu Liao; Chao-Chi Ho; Kuan-Yu Chen; Tzu-Hsiu Tsai; Chia-Lin Hsu; Kang-Yi Su; Yih-Leong Chang; Chen-Tu Wu; Chia-Chi Hsu; Bin-Chi Liao; Wei-Hsun Hsu; Jih-Hsiang Lee; Chia-Chi Lin; Jin-Yuan Shih; James C.-H. Yang; Chong-Jen Yu | European Journal of Cancer | 9 | 19 | |
| 2020 | Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib | Yang C.-Y.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. | Oncologist | 6 | 7 | |
| 2017 | Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression | Chen C.-Y.; Chen Y.-Y.; Chen J.J.W.; Chen K.-Y.; CHAO-CHI HO; Shih J.-Y.; Chang Y.-L.; Yu C.-J.; Yang P.-C. | Oncotarget | 4 | 5 | |
| 2019 | Atypical cells in pathology of endobronchial ultrasound-guided transbronchial biopsy of peripheral pulmonary lesions: incidence and clinical significance | Huang C.-T.; Tsai Y.-J.; CHAO-CHI HO; Yu C.-J. | Surgical Endoscopy | 3 | 3 | |
| 2014 | Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer | Lee J.-H.; Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; Chang Y.-C.; Yu C.-J.; Shih J.-Y.; Lin C.-C.; Chen K.-Y.; CHAO-CHI HO; Laio W.-Y.; Yang P.-C.; Yang J.C.-H. | Journal of Thoracic Oncology | 38 | 34 | |
| 2018 | Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer Patients | Wu T.-H.; Hsiue E.H.-C.; Lee J.-H.; Lin C.-C.; Liao W.-Y.; CHAO-CHI HO; Shih J.-Y.; Yu C.-J.; Yang J.C.-H. | Clinical Lung Cancer | 7 | 12 | |
